Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
2.38
Dollar change
-0.02
Percentage change
-0.83
%
Index- P/E- EPS (ttm)-0.38 Insider Own35.79% Shs Outstand78.46M Perf Week-3.64%
Market Cap192.35M Forward P/E- EPS next Y-0.41 Insider Trans0.00% Shs Float51.89M Perf Month13.60%
Income-30.39M PEG- EPS next Q-0.11 Inst Own23.67% Short Float0.52% Perf Quarter18.41%
Sales7.04M P/S27.32 EPS this Y-16.58% Inst Trans-2.73% Short Ratio0.88 Perf Half Y64.14%
Book/sh0.58 P/B4.08 EPS next Y8.05% ROA-18.14% Short Interest0.27M Perf Year-33.70%
Cash/sh1.63 P/C1.46 EPS next 5Y- ROE-52.57% 52W Range1.11 - 3.70 Perf YTD20.20%
Dividend Est.- P/FCF8.86 EPS past 5Y21.74% ROI-46.23% 52W High-35.66% Beta0.21
Dividend TTM- Quick Ratio3.54 Sales past 5Y44.49% Gross Margin- 52W Low114.41% ATR (14)0.17
Dividend Ex-Date- Current Ratio3.54 EPS Y/Y TTM59.94% Oper. Margin-535.55% RSI (14)58.89 Volatility5.45% 8.20%
Employees- Debt/Eq0.48 Sales Y/Y TTM64.55% Profit Margin-431.93% Recom1.50 Target Price4.66
Option/ShortYes / Yes LT Debt/Eq0.44 EPS Q/Q49.90% Payout- Rel Volume0.14 Prev Close2.40
Sales Surprise-65.78% EPS Surprise-478.92% Sales Q/Q321.20% EarningsMar 13 BMO Avg Volume310.37K Price2.38
SMA208.00% SMA5010.79% SMA20037.21% Trades Volume43,391 Change-0.83%
Date Action Analyst Rating Change Price Target Change
Nov-08-23Upgrade Chardan Capital Markets Neutral → Buy $2
Mar-30-23Upgrade JMP Securities Mkt Perform → Mkt Outperform $1.50 → $5
Dec-22-22Upgrade Cantor Fitzgerald Neutral → Overweight $0.80 → $5
Feb-14-22Downgrade Citigroup Buy → Neutral $37 → $1.70
Feb-11-22Downgrade Stifel Buy → Hold $20 → $3
Feb-11-22Downgrade Raymond James Strong Buy → Mkt Perform
Feb-01-22Initiated Raymond James Strong Buy $19
May-03-21Initiated Stifel Buy $20
Mar-25-21Reiterated Citigroup Buy $33 → $44
Nov-03-20Resumed Cantor Fitzgerald Overweight $22
Mar-13-24 07:00AM
Feb-15-24 07:00AM
Jan-19-24 07:00AM
Jan-05-24 07:00AM
Dec-28-23 08:44AM
07:30AM Loading…
Dec-08-23 07:30AM
Nov-07-23 07:00AM
Nov-06-23 07:00AM
Sep-28-23 08:00AM
Sep-27-23 07:00AM
Sep-07-23 08:00AM
Aug-08-23 06:37AM
Aug-03-23 07:00AM
Aug-01-23 07:00AM
Jul-06-23 07:00AM
06:02AM Loading…
Jun-28-23 06:02AM
May-18-23 07:02AM
May-16-23 07:00AM
May-09-23 08:00AM
Apr-20-23 08:00AM
Apr-18-23 08:00AM
Mar-29-23 12:30PM
08:00AM
Mar-14-23 08:00AM
Mar-07-23 08:00AM
Feb-28-23 08:00AM
Feb-01-23 05:11AM
Dec-29-22 11:36AM
Dec-23-22 12:14PM
Dec-22-22 09:12AM
08:53AM Loading…
08:53AM
06:15AM
06:00AM
05:28AM
Nov-14-22 04:30PM
Nov-11-22 05:54AM
Nov-09-22 08:25AM
07:00AM
Nov-03-22 07:00AM
Aug-12-22 02:05PM
Aug-11-22 02:48PM
07:00AM
Aug-04-22 10:25AM
07:00AM
Jul-08-22 07:06AM
Jun-28-22 07:00AM
Jun-01-22 07:00AM
May-09-22 07:00AM
May-05-22 08:15PM
04:30PM
May-03-22 09:55AM
Apr-28-22 03:02PM
Apr-26-22 04:10PM
Apr-19-22 04:30PM
Apr-13-22 09:49AM
07:00AM
Apr-12-22 04:30PM
Apr-04-22 07:00AM
Mar-23-22 04:30PM
Mar-07-22 07:00AM
Feb-24-22 08:35AM
07:00AM
Feb-17-22 03:02PM
Feb-14-22 06:23PM
04:38PM
Feb-11-22 01:24PM
07:00AM
Feb-10-22 07:19PM
Feb-07-22 04:30PM
Feb-02-22 02:11AM
Jan-04-22 07:00AM
Dec-30-21 07:00AM
Dec-16-21 07:00AM
Nov-18-21 04:01PM
Nov-11-21 07:00AM
Nov-08-21 04:30PM
Nov-04-21 10:05AM
07:00AM
Oct-19-21 10:44AM
Oct-04-21 08:00AM
Sep-13-21 08:32AM
Sep-10-21 05:16AM
Sep-09-21 12:01PM
06:58AM
Sep-08-21 04:15PM
04:01PM
Sep-06-21 04:15PM
Sep-03-21 08:00AM
Aug-11-21 04:30PM
Aug-05-21 08:45AM
07:00AM
Jul-26-21 10:59AM
Jul-19-21 08:38AM
Jun-10-21 07:00AM
May-18-21 07:32AM
May-06-21 09:05AM
07:00AM
May-04-21 09:35AM
07:00AM
Apr-23-21 07:00AM
ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012, and is headquartered in Leiden, the Netherlands.